Cue Biopharma

NASDAQ CUE

Data sourced from

and

Download Data

Cue Biopharma Working Capital to Current Liabilities Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -73.27%

Cue Biopharma Working Capital to Current Liabilities Ratio 1 year YoY Change (%) is -73.27% for the Trailing 12 Months (TTM) ending March 31, 2024, a -375.09% change year over year. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Cue Biopharma Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 5.50, a 26.64% change year over year.
Cue Biopharma Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 4.34, a -6.34% change year over year.
Cue Biopharma Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 4.63, a 64.14% change year over year.
Cue Biopharma Working Capital to Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 2.82, a -63.60% change year over year.

NASDAQ: CUE

Cue Biopharma

CEO	Mr. Daniel R. Passeri J.D., M.Sc., MSc.
IPO Date	Jan. 2, 2018
Location	United States
Headquarters	21 Erie Street, Cambridge, MA, United States, 02139
Employees	53
Sector	Healthcare
Industry	Biotechnology

Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Key trends